Sprycel Drug Sales & Forecast

BMS drug Sprycel (dasatinib) is an oral inhibitor of multiple tyrosine kinase indicated for the first-line treatment of patients with Philadelphia chromosome-positive CML in chronic phase, the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase CML with resistance or intolerance to prior therapy, including Gleevec (imatinib mesylate) and the treatment of children and adolescents aged 1 year to 18 years with chronic phase Philadelphia chromosome-positive CML. MNG Tracker report title “Sprycel Drug Sales & Forecast” provides historical as well as estimated Sprycel sales in Global, United States and Rest of the World market. This is single page report which also covered key factors for the growth/decline of the Sprycel sales in Global, United States and Rest of the World market.